search
Back to results

Assessment of the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate Osteoarthritis (A Paniculata)

Primary Purpose

Knee Osteoarthritis

Status
Completed
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Placebo
Andrographis Paniculata
Andrographis Paniculata
Sponsored by
Vedic Lifesciences Pvt. Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female subjects in the age range of 40 - 70 years (both inclusive).
  2. Body mass index (BMI) must be ≥ 25 and < 29.9 kg/m2.
  3. Radiographic evidence of grade I- II osteoarthritis of knee joint, based on the Kellgren and Lawrence radiographic entry criteria with WOMAC pain score in range of 10-16.
  4. History of primary idiopathic osteoarthritis of the knee characterized by pain of mild to moderate intensity which requires intake of analgesics.
  5. Self-reported difficulty in at least one of the following activities attributed to knee pain: walking a distance of 400 metres, getting in and out of the car, going up and down the stairs or stiffness observed in the knee if > 30 minutes in the same position.
  6. Female subjects of child-bearing age must be willing to use the accepted methods of contraception during the course of the study.
  7. Ability to provide written informed consent.

Exclusion Criteria:

  1. Prior or ongoing medical conditions (e.g. concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ECG findings or laboratory abnormalities that in the investigator's opinion could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed or could impair the assessment of study results.
  2. History of surgery or major trauma to the study joint.
  3. History of arthroscopic surgery or intervention on the study joint.
  4. Subjects who have received intra-articular steroids or hyaluronic acid within the last three months.
  5. Signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination after the washout period.
  6. Subjects awaiting a replacement of knee or hip joint.
  7. Subjects with other conditions that cause pain.
  8. Subjects with deformity of the knee joint.
  9. Subject who are significantly incapacitated or disabled and would be categorized as ACR Functional Class IV (largely or wholly incapacitated), or unable to walk without assistive devices.
  10. Subjects with other known rheumatic or inflammatory disease such as rheumatoid arthritis, osteomyelitis and bone metastasis.
  11. Other pathologic lesions on X-rays of knee.
  12. Positive hepatitis B surface antigen, Hepatitis C antibody, Anti human immunodeficiency virus (HIV) antibody test, or VDRL.
  13. History of bleeding disorders.
  14. Inability to comply with the protocol requirements.
  15. Participation in any other clinical trial within 3 months of registering in this trial.
  16. Women of child-bearing potential with a positive pregnancy test or who are lactating.

Sites / Locations

  • Nidaan Hospital, A/1, Adinath Society, Near Dosti Estate, Opposite Antop Hill Post Office, Wadala(West)
  • Ayush nursing Home, Gaurav vista, Gaurav Garden,BunderpakhadiRoad, Kandivali(West)
  • Siddhant Clinic, Shop No. 17, Lenyadri Cooperative Housing Society, Sector 19A, Nerul(East),Navi Mumbai -400706, Maharashtra
  • Orthopaedic Clinic, 213, 2nd floor, Shiv Centre, Plot no. 72, Sector-17, Vashi, Navi Mumbai.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Arm Label

Placebo

Andrographis Paniculata 150

Andrographis Paniculata 300

Arm Description

Microcrystalline cellulose

Andrographis Paniculata 150 mg

Andrographis Paniculata 300 mg

Outcomes

Primary Outcome Measures

WOMAC pain score
Change in WOMAC pain score

Secondary Outcome Measures

WOMAC stiffness score
Change in WOMAC stiffness score
WOMAC physical function score
Change in WOMAC physical function score
SF-36
Change in SF-36's various component scores.
FACIT score
Change in FACIT score
Rescue medication consumption
Change in rescue medication consumption.

Full Information

First Posted
August 23, 2017
Last Updated
July 8, 2021
Sponsor
Vedic Lifesciences Pvt. Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03262792
Brief Title
Assessment of the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate Osteoarthritis
Acronym
A Paniculata
Official Title
A Double-blind, Randomized, Placebo Controlled Study to Assess the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate Osteoarthritis Over a 12-weeks Period
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
December 13, 2017 (Actual)
Primary Completion Date
July 30, 2018 (Actual)
Study Completion Date
August 27, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vedic Lifesciences Pvt. Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a 12 weeks randomized, double-blind, placebo-controlled clinical study to assess the effect of Andrographis Paniculata at low dose of 300 mg/day and high dose of 600 mg/day in the study population in the age range of 40-70 years and suffering from mild-moderate OA.
Detailed Description
In this study, we will assess the efficacy parameters such as effect on various joint health parameters (pain, stiffness and physical activity) by using WOMAC scale. The individuals with knee OA suffer from an increased impact on their activities of daily living, which leads to losses in labor relations, leisure, social life, and sleeping quality, leading also to important decrease in their quality of life. Thus, an important outcome to be evaluated in this study is quality of life of these individuals which will be assessed by SF-36 self-reported questionnaire. One of the aims of this study is therefore to investigate the levels of different dimensions of fatigue in knee OA and to assess changes in fatigue after the treatment targeting pain reduction and physical functioning by the use of FACIT-fatigue questionnaire. Effect of the treatment on rescue medication consumption which is directly proportional to the degree of pain will also be captured via this study. The hepatic (SGOT and SGPT) and renal (serum creatinine) safety biomarkers will be assessed to investigate the effect of chronic use of Andrographis Paniculata on liver and kidneys.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, double-blind, placebo controlled, parallel groups study.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
108 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Microcrystalline cellulose
Arm Title
Andrographis Paniculata 150
Arm Type
Active Comparator
Arm Description
Andrographis Paniculata 150 mg
Arm Title
Andrographis Paniculata 300
Arm Type
Active Comparator
Arm Description
Andrographis Paniculata 300 mg
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Microcrystalline cellulose
Intervention Type
Dietary Supplement
Intervention Name(s)
Andrographis Paniculata
Intervention Description
Andrographis Paniculata 150 mg
Intervention Type
Dietary Supplement
Intervention Name(s)
Andrographis Paniculata
Intervention Description
Andrographis Paniculata 300 mg
Primary Outcome Measure Information:
Title
WOMAC pain score
Description
Change in WOMAC pain score
Time Frame
84 days
Secondary Outcome Measure Information:
Title
WOMAC stiffness score
Description
Change in WOMAC stiffness score
Time Frame
84 days
Title
WOMAC physical function score
Description
Change in WOMAC physical function score
Time Frame
84 days
Title
SF-36
Description
Change in SF-36's various component scores.
Time Frame
84 days
Title
FACIT score
Description
Change in FACIT score
Time Frame
84 days
Title
Rescue medication consumption
Description
Change in rescue medication consumption.
Time Frame
84 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects in the age range of 40 - 70 years (both inclusive). Body mass index (BMI) must be ≥ 25 and < 29.9 kg/m2. Radiographic evidence of grade I- II osteoarthritis of knee joint, based on the Kellgren and Lawrence radiographic entry criteria with WOMAC pain score in range of 10-16. History of primary idiopathic osteoarthritis of the knee characterized by pain of mild to moderate intensity which requires intake of analgesics. Self-reported difficulty in at least one of the following activities attributed to knee pain: walking a distance of 400 metres, getting in and out of the car, going up and down the stairs or stiffness observed in the knee if > 30 minutes in the same position. Female subjects of child-bearing age must be willing to use the accepted methods of contraception during the course of the study. Ability to provide written informed consent. Exclusion Criteria: Prior or ongoing medical conditions (e.g. concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ECG findings or laboratory abnormalities that in the investigator's opinion could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed or could impair the assessment of study results. History of surgery or major trauma to the study joint. History of arthroscopic surgery or intervention on the study joint. Subjects who have received intra-articular steroids or hyaluronic acid within the last three months. Signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination after the washout period. Subjects awaiting a replacement of knee or hip joint. Subjects with other conditions that cause pain. Subjects with deformity of the knee joint. Subject who are significantly incapacitated or disabled and would be categorized as ACR Functional Class IV (largely or wholly incapacitated), or unable to walk without assistive devices. Subjects with other known rheumatic or inflammatory disease such as rheumatoid arthritis, osteomyelitis and bone metastasis. Other pathologic lesions on X-rays of knee. Positive hepatitis B surface antigen, Hepatitis C antibody, Anti human immunodeficiency virus (HIV) antibody test, or VDRL. History of bleeding disorders. Inability to comply with the protocol requirements. Participation in any other clinical trial within 3 months of registering in this trial. Women of child-bearing potential with a positive pregnancy test or who are lactating.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shalini Srivastava, MD
Organizational Affiliation
Vedic Lifesciences
Official's Role
Study Director
Facility Information:
Facility Name
Nidaan Hospital, A/1, Adinath Society, Near Dosti Estate, Opposite Antop Hill Post Office, Wadala(West)
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400031
Country
India
Facility Name
Ayush nursing Home, Gaurav vista, Gaurav Garden,BunderpakhadiRoad, Kandivali(West)
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400067
Country
India
Facility Name
Siddhant Clinic, Shop No. 17, Lenyadri Cooperative Housing Society, Sector 19A, Nerul(East),Navi Mumbai -400706, Maharashtra
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400706
Country
India
Facility Name
Orthopaedic Clinic, 213, 2nd floor, Shiv Centre, Plot no. 72, Sector-17, Vashi, Navi Mumbai.
City
Mumbai
State/Province
Maharashtra
Country
India

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
http://hpingredients.com/products/premier-ingredients/paractin/
Description
Related Info

Learn more about this trial

Assessment of the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate Osteoarthritis

We'll reach out to this number within 24 hrs